Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Kaiser

Showing results (81-90 of 160) with videos related to

Pageof 16
Sort By:
Leukemia Research|September 9, 2011
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemiaAndrea Kühnl, Martin Kaiser, Martin Neumann, et al.
European Journal of Haematology|December 24, 2009
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myelomaMartin Kaiser, Britta Lamottke, Maren Mieth, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 31, 2024
An Attribution of Value Framework for Combination TreatmentsAndrew H Briggs, Alexis Doyle-Connolly, John Schneider, et al.
Research Square|March 30, 2023
Risk factors for eight common cancers revealed from a phenome-wide Mendelian randomisation analysis of 378,142 cases and 485,715 controlsMolly Went, Amit Sud, Charlie Mills, et al.
European Journal of Haematology|November 17, 2007
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphomaUlrike Heider, Ivana von Metzler, Martin Kaiser, et al.
American Journal of Hematology|September 10, 2025
European Myeloma Network Consensus Statement on Functional High-Risk Multiple MyelomaSueh-Li Lim, Monika Engelhardt, Evangelos Terpos, et al.
Nature Communications|March 26, 2024
Phenome-wide Mendelian randomisation analysis of 378,142 cases reveals risk factors for eight common cancersMolly Went, Amit Sud, Charlie Mills, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2021
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four TrialSarah Brown, Charlotte Pawlyn, Avie-Lee Tillotson, et al.
Medrxiv : the Preprint Server for Health Sciences|April 17, 2023
Risk factors for eight common cancers revealed from a phenome-wide Mendelian randomisation analysis of 378,142 cases and 485,715 controlsMolly Went, Amit Sud, Charlie Mills, et al.
European Journal of Haematology|March 12, 2008
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myelomaMartin Kaiser, Maren Mieth, Peter Liebisch, et al.
Pageof 16

Showing results (81-90 of 160) with videos related to

Sort By:
Pageof 16
Leukemia Research|September 9, 2011
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemiaAndrea Kühnl, Martin Kaiser, Martin Neumann, et al.
European Journal of Haematology|December 24, 2009
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myelomaMartin Kaiser, Britta Lamottke, Maren Mieth, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 31, 2024
An Attribution of Value Framework for Combination TreatmentsAndrew H Briggs, Alexis Doyle-Connolly, John Schneider, et al.
Research Square|March 30, 2023
Risk factors for eight common cancers revealed from a phenome-wide Mendelian randomisation analysis of 378,142 cases and 485,715 controlsMolly Went, Amit Sud, Charlie Mills, et al.
European Journal of Haematology|November 17, 2007
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphomaUlrike Heider, Ivana von Metzler, Martin Kaiser, et al.
American Journal of Hematology|September 10, 2025
European Myeloma Network Consensus Statement on Functional High-Risk Multiple MyelomaSueh-Li Lim, Monika Engelhardt, Evangelos Terpos, et al.
Nature Communications|March 26, 2024
Phenome-wide Mendelian randomisation analysis of 378,142 cases reveals risk factors for eight common cancersMolly Went, Amit Sud, Charlie Mills, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2021
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four TrialSarah Brown, Charlotte Pawlyn, Avie-Lee Tillotson, et al.
Medrxiv : the Preprint Server for Health Sciences|April 17, 2023
Risk factors for eight common cancers revealed from a phenome-wide Mendelian randomisation analysis of 378,142 cases and 485,715 controlsMolly Went, Amit Sud, Charlie Mills, et al.
European Journal of Haematology|March 12, 2008
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myelomaMartin Kaiser, Maren Mieth, Peter Liebisch, et al.
Pageof 16